Related references
Note: Only part of the references are listed.Development of Gene Therapeutics for Head and Neck Cancer in China: From Bench to Bedside
Wei Guo et al.
HUMAN GENE THERAPY (2018)
Induction of Oxidants Distinguishes Susceptibility of Prostate Carcinoma Cell Lines to p53 Gene Transfer Mediated by an Improved Adenoviral Vector
Rodrigo Esaki Tamura et al.
HUMAN GENE THERAPY (2017)
Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
A comprehensive review of immunotherapies in prostate cancer
Manuel Caitano Maia et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Autoregulated expression of p53 from an adenoviral vector confers superior tumor inhibition in a model of prostate carcinoma gene therapy
Rodrigo Esaki Tamura et al.
CANCER BIOLOGY & THERAPY (2016)
Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer
Masahiro Nozawa et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2015)
Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme
Axel Heidenreich et al.
EUROPEAN JOURNAL OF CANCER (2014)
Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters
Jayne Loughery et al.
NUCLEIC ACIDS RESEARCH (2014)
Combined p19Arf and interferon-beta gene transfer enhances cell death of B16 melanoma in vitro and in vivo
C. A. Merkel et al.
CANCER GENE THERAPY (2013)
Functional p53 determines docetaxel sensitivity in prostate cancer cells
Chengfei Liu et al.
PROSTATE (2013)
AAVPG: A vigilant vector where transgene expression is induced by p53
Marcio C. Bajgelman et al.
VIROLOGY (2013)
Docetaxel and 5-fluorouracil induce human p53 tumor suppressor gene transcription via a short sequence at core promoter element
Jui-Chuan Chuang et al.
TOXICOLOGY IN VITRO (2012)
Resistance to Docetaxel-Induced Apoptosis in Prostate Cancer Cells by p38/p53/p21 Signaling
Lu Gan et al.
PROSTATE (2011)
Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6
Christian A. Merkel et al.
BMC CANCER (2010)
Efficacy of Oncolytic Mutants Targeting pRb and p53 Pathways Is Synergistically Enhanced When Combined with Cytotoxic Drugs in Prostate Cancer Cells and Tumor Xenografts
Suresh Radhakrishnan et al.
HUMAN GENE THERAPY (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Development of an adenoviral vector with robust expression driven by p53
Marcio C. Bajgelman et al.
VIROLOGY (2008)
A rapid and efficient method for purification of recombinant adenovirus with arginine-glycine-aspartic acid-modified fibers
Henry H. Peng et al.
ANALYTICAL BIOCHEMISTRY (2006)
Current status of gendicine in China: Recombinant human Ad-p53 agent for treatment of cancers
ZH Peng
HUMAN GENE THERAPY (2005)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and Clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain
DS Ernst et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats
S Cisternino et al.
BRITISH JOURNAL OF PHARMACOLOGY (2003)
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer
W Berry et al.
JOURNAL OF UROLOGY (2002)
Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells
R Sasaki et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2001)
Share Paper
